Sustained Improvement in Patient-Reported Outcomes With Continued Apremilast Treatment over 104 Weeks in Patients With Moderate to Severe Psoriasis. J of Skin 2018, 2 (S1), S23. https://doi.org/10.25251/skin.2.supp.23.